Eli Lilly announced plans to manufacture its new weight loss pill, orforglipron, in the U.S., with global distribution set to begin in 2026, Bloomberg reported April 18. The move comes as President Donald Trump presses companies to shift to domestic…
GLP-1s
As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal policy In early April, CMS rejected a Biden-era…
Eli Lilly completed a phase 3 trial for its weight loss drug, orforglipron, which showed promising results in evaluating its safety and efficacy for adults with Type 2 diabetes and inadequate glycemic control. The once-daily oral GLP-1 receptor agonist significantly…
At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of Internal Medicine. Researchers at Mass…
Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant “experienced potential drug-induced liver injury,” the company said April 14. In dose-optimization studies, once-daily danuglipron met pharmacokinetic endpoints and showed potential for promising…
Advertisement
CMS said April 4 it will not move forward with a Biden-era proposal to allow Medicare coverage of GLP-1 drugs when prescribed solely for weight loss. Three notes: 1. While the agency is not currently moving forward with a proposal…
Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine. A common challenge for physicians prescribing GLP-1s is whether to increase…
A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes. The research, published April 1 in the Annals of Internal Medicine, showed the number…
Four blockbuster GLP-1 medications are expected to be among the 10 best-selling drugs in 2026, accounting for $66.8 billion in global sales, according to market research company Statista Statista predicts Ozempic will yield $22.3 billion in 2026, followed by Mounjaro…
With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic and Wegovy set for later this spring, the agency is meeting resistance from telehealth companies and compounding pharmacies that are…